1y return+112.5%S&P 500 +20.9%
3y return+148.3%S&P 500 +68.5%
5y return+60.8%S&P 500 +74.5%
These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.
$100 invested in its stock picks
Since March 31, 2021: $150 against $188 in the S&P 500.2
Affinity Asset Advisors, LLCS&P 500 (SPY)
Top holdings
At the end of June 30, 2026. Change is in shares since the quarter before.2
| Stock | Value | Share of portfolio | Change |
|---|---|---|---|
| Roivant Sciences LtdCUSIP G76279101 | $132.7M | 6.6% | +33.9% |
| Apogee Therapeutics IncCUSIP 03770N101 | $131.0M | 6.5% | −23.2% |
| SYRESpyre Therapeutics Inc | $113.6M | 5.6% | |
| XENEXenon Pharmaceuticals Inc | $96.3M | 4.8% | −4.8% |
| ERASErasca Inc | $96.2M | 4.8% | −1.9% |
| INSMInsmed Inc | $69.3M | 3.4% | +35.4% |
| PRAXPraxis Precision Medicines I | $61.9M | 3.1% | +8.8% |
| Alkermes PLCCUSIP G01767105 | $58.9M | 2.9% | −16.7% |
| ORKAOruka Therapeutics Inc | $56.2M | 2.8% | +18.1% |
| ANABAnaptysbio Inc | $55.8M | 2.8% | −12.1% |
| AVTXAvalo Therapeutics Inc | $53.6M | 2.7% | +116.3% |
| CYTKCytokinetics Inc | $46.9M | 2.3% | −21.5% |
| RVMDRevolution Medicines Inc | $46.8M | 2.3% | +150.0% |
| ABVXAbivax Sa | $44.0M | 2.2% | −18.5% |
| TRAXFirst Tracks Biotherapeutics | $40.9M | 2.0% | New |
| DNTHDianthus Therapeutics Inc | $39.0M | 1.9% | +14.3% |
| STROSutro Biopharma Inc | $38.9M | 1.9% | +9.6% |
| Nuvalent IncCUSIP 670703107 | $34.0M | 1.7% | −8.3% |
| TRVITrevi Therapeutics Inc | $33.6M | 1.7% | −10.0% |
| OVIDOvid Therapeutics Inc | $27.3M | 1.4% | −4.6% |
| LXEOLexeo Therapeutics Inc | $27.0M | 1.3% | +15.0% |
| CLDXCelldex Therapeutics Inc New | $26.0M | 1.3% | +40.0% |
| BLTEBelite Bio Inc | $25.4M | 1.3% | +153.8% |
| ELVNEnliven Therapeutics Inc | $25.4M | 1.3% | −14.8% |
| Forte Biosciences IncCUSIP 34962G208 | $24.3M | 1.2% | +13.2% |
Best picks still held
How each current holding has done since the quarter it first appeared in its filings (up to six years back).
| Stock | Held since | Return since | Now worth |
|---|---|---|---|
| SYRESpyre Therapeutics Inc | September 30, 2023 | +624.7% | $113.6M |
| Apogee Therapeutics IncCUSIP 03770N101 | September 30, 2023 | +523.1% | $131.0M |
| RVMDRevolution Medicines Inc | September 30, 2025 | +301.0% | $46.8M |
| ORKAOruka Therapeutics Inc | September 30, 2024 | +288.3% | $56.2M |
| Roivant Sciences LtdCUSIP G76279101 | March 31, 2025 | +250.7% | $132.7M |
| TVTXTravere Therapeutics Inc | December 31, 2024 | +226.1% | $17.0M |
| PTGXProtagonist Therapeutics Inc | December 31, 2024 | +217.6% | $21.1M |
| TRVITrevi Therapeutics Inc | March 31, 2025 | +196.5% | $33.6M |
| STROSutro Biopharma Inc | December 31, 2025 | +186.9% | $38.9M |
| SVRASavara Inc | June 30, 2025 | +170.2% | $15.5M |
Sold off last quarter
- Centessa Pharmaceuticals PLCCUSIP 152309100 was $55.6M
- Arcellx IncCUSIP 03940C100 was $41.7M
- Terns Pharmaceuticals IncCUSIP 880881107 was $29.7M
- Ascendis Pharma A/sCUSIP 04351P101 was $21.7M
- BBIOBridgebio Pharma Inc was $11.1M
- Wave Life Sciences LtdCUSIP Y95308105 was $10.2M
- Engene Holdings IncCUSIP 29286M105 was $4.2M
- CORTCorcept Therapeutics Inc was $2.0M
- Kezar Life Sciences IncCUSIP 49372L209 was $1.7M
Quarter by quarter
| Quarter | Its picks | S&P 500 |
|---|---|---|
| June 30, 2026 | +20.4% | +14.8% |
| March 31, 2026 | +6.8% | −4.6% |
| December 31, 2025 | +30.3% | +2.4% |
| September 30, 2025 | +26.8% | +7.8% |
| June 30, 2025 | +6.3% | +10.5% |
| March 31, 2025 | −15.1% | −4.6% |
| December 31, 2024 | −5.6% | +2.1% |
| September 30, 2024 | +13.4% | +5.4% |
| June 30, 2024 | −13.3% | +4.0% |
| March 31, 2024 | +18.5% | +10.0% |
| December 31, 2023 | +33.5% | +11.2% |
| September 30, 2023 | −11.8% | −3.6% |
| June 30, 2023 | +13.1% | +8.3% |
| March 31, 2023 | −2.3% | +7.0% |
| December 31, 2022 | +9.9% | +7.1% |
| September 30, 2022 | +4.1% | −5.3% |
| June 30, 2022 | −20.1% | −16.5% |
| March 31, 2022 | −14.4% | −4.9% |
| December 31, 2021 | −17.8% | +10.7% |
| September 30, 2021 | −8.9% | +0.3% |
Sources
Every number on this page points here. Each one links to the public record.
- 1SEC EDGAR: Affinity Asset Advisors, LLC Form 13F filingshttps://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1773195&type=13F-HR&dateb=&owner=include&count=40CIK 1773195
- 2SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/1773195/000101143826000516/Filed August 13, 2026 · accession 0001011438-26-000516